Literature DB >> 27368671

Successful treatment of refractory giant cell arteritis with etanercept.

Masaaki Fujita1, Yuya Tabuchi2, Masato Yagita2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27368671     DOI： 10.1007/s00296-016-3521-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  11 in total

1.  Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs.

Authors:  P Airò; C M Antonioli; M Vianelli; P Toniati
Journal:  Rheumatology (Oxford)       Date:  2002-03       Impact factor: 7.580

2.  Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis.

Authors:  Ana García-Martínez; José Hernández-Rodríguez; Georgina Espígol-Frigolé; Sergio Prieto-González; Montserrat Butjosa; Marta Segarra; Ester Lozano; Maria C Cid
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

3.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis.

Authors:  G G Hunder; D A Bloch; B A Michel; M B Stevens; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt; J T Lie
Journal:  Arthritis Rheum       Date:  1990-08

4.  Treatment of refractory temporal arteritis with adalimumab.

Authors:  M Mubashir Ahmed; Eisha Mubashir; Samina Hayat; Marjorie Fowler; Seth Mark Berney
Journal:  Clin Rheumatol       Date:  2006-08-30       Impact factor: 2.980

5.  Amaurosis in patients with giant cell arteritis: treatment with anti-tumour necrosis factor-alpha.

Authors:  S V Torrente; R C Güerri; C Pérez-García; P Benito; J Carbonell
Journal:  Intern Med J       Date:  2007-04       Impact factor: 2.048

6.  Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.

Authors:  Gary S Hoffman; Maria C Cid; Karen E Rendt-Zagar; Peter A Merkel; Cornelia M Weyand; John H Stone; Carlo Salvarani; Weichun Xu; Sudha Visvanathan; Mahboob U Rahman
Journal:  Ann Intern Med       Date:  2007-05-01       Impact factor: 25.391

7.  Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis.

Authors:  J Hernández-Rodríguez; M Segarra; C Vilardell; M Sánchez; A García-Martínez; M J Esteban; C Queralt; J M Grau; A Urbano-Márquez; A Palacín; D Colomer; M C Cid
Journal:  Rheumatology (Oxford)       Date:  2003-12-16       Impact factor: 7.580

8.  Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial.

Authors:  Raphaèle Seror; Gabriel Baron; Eric Hachulla; Michel Debandt; Claire Larroche; Xavier Puéchal; François Maurier; Benoît de Wazieres; Thomas Quéméneur; Philippe Ravaud; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2013-07-29       Impact factor: 19.103

9.  A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.

Authors:  V M Martínez-Taboada; V Rodríguez-Valverde; L Carreño; J López-Longo; M Figueroa; J Belzunegui; E M Mola; G Bonilla
Journal:  Ann Rheum Dis       Date:  2007-12-17       Impact factor: 19.103

Review 10.  Biological therapy for systemic vasculitis: a systematic review.

Authors:  Lucía Silva-Fernández; Estíbaliz Loza; Víctor M Martínez-Taboada; Ricardo Blanco; Iñigo Rúa-Figueroa; José María Pego-Reigosa; Santiago Muñoz-Fernández
Journal:  Semin Arthritis Rheum       Date:  2013-08-24       Impact factor: 5.532
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.